S M Mangsbo
Overview
Explore the profile of S M Mangsbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eltahir M, FLETCHER E, Dynesius L, Jarblad J, Lord M, Lauren I, et al.
Int Immunopharmacol
. 2020 Dec;
90:107226.
PMID: 33316742
Rituximab is widely used in the treatment of haematological malignancies, including chronic lymphocytic leukaemia (CLL), the most common leukaemia in adults. However, some patients, especially those with high tumour burden,...
2.
Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich L, Christiansson L, et al.
Gene Ther
. 2016 Dec;
24(2):92-103.
PMID: 27906162
CD40 is an interesting target in cancer immunotherapy due to its ability to stimulate T-helper 1 immunity via maturation of dendritic cells and to drive M2 to M1 macrophage differentiation....
3.
Ellmark P, Mangsbo S, Furebring C, Totterman T, Norlen P
Oncoimmunology
. 2015 Jul;
4(7):e1011484.
PMID: 26140231
Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of...
4.
Liljenfeldt L, Dieterich L, Dimberg A, Mangsbo S, Loskog A
Cancer Gene Ther
. 2014 Feb;
21(3):95-102.
PMID: 24481488
CD40 ligand (CD40L) is a potent stimulator of tumor immunity via its activation of dendritic cells, which in turn initiate T-cell activation. However, T cells are inhibited by suppressive myeloid...
5.
Lund T, Mangsbo S, Scholz H, Gjorstrup P, Totterman T, Korsgren O, et al.
Exp Clin Endocrinol Diabetes
. 2010 Feb;
118(4):237-44.
PMID: 20119897
Background: In clinical islet transplantation, inflammatory responses initiated by the transplanted islets and by the host immune system cause acute and chronic graft loss. The resolution of acute inflammation is...